Hema Now: Episode 8: What’s Next in Lymphoma Diagnosis and Treatment?
Uncover the future of lymphoma care with Marc Hoffman, Professor, Hematologic Malignancies at the University of Kansas Medical Center.
Related Articles
Clinical Trials Are Testing Ways to Prevent Breast Cancer
At the 2024 San Antonio Breast Cancer Symposium, researchers discussed clinical trials for vaccines and other ways to prevent breast cancer.
Call for EIC – CA: A Cancer Journal for Clinicians – Wiley Online Library
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
AI Detects Parkinson’s with Near-Perfect Accuracy by Analysing Emotions
EEG-based emotional analysis achieves near-perfect accuracy in Parkinson’s diagnosis, offering a non-invasive, objective method.
APCCC Diagnostics 2025 – APCCC
The diagnostic abilities for assessing prostate cancer patients have significantly evolved in the last years. Ranging from advanced imaging modalities for detection, new innovative liquid…
FY25 FDA Broad Agency Announcement – Q&A Session
FY25 FDA Broad Agency Announcement – Question and Answer Session
Fundamentals of HCT Training Course
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…
Cell Proliferation: Vol 58, No 1
Cell Proliferation is an open access cell biology journal covering stem cells, cancer, regenerative medicine, tissue engineering, cell cycle control, cell senescence & death, and…
RP1 Combination Shows Response, Safety in Advanced Melanoma
Vusolimogene oderparepvec plus nivolumab showed responses and a favorable safety profile in advanced melanoma post-anti–PD-1 therapy, per phase 2 IGNYTE trial data.
Lower-intensity therapy for good-risk B-ALL
In this issue of Blood, Purvis et al1 have demonstrated that most children with B-lineage acute lymphoblastic leukemia (B-ALL) within the good-risk categor
